COMPARISON OF EARLY TREATMENT- EMERGENT COMPLICATIONS OF STAGE III A NON-SMALL CELL CARCINOMA (NSCLC STAGE III A) IN PATIENTS TREATED WITH NEOADJUVANT CHEMORADIOTHERAPY (NHLT), (NCHT), AND NEOADJUVANT CHEMOTHERAPY AND ADJUVANT RADIATION THERAPY
ARTICLE PDF (Українська)

Keywords

non-small cell lung cancer
neoadjuvant therapy
chemoradiotherapy
early complications

How to Cite

Malyarchuk, K. A., Ganul, A. V., Borysyuk, B. O., Bororov, L. V., Shevchenko, A. I., & Sovenko, V. M. (2023). COMPARISON OF EARLY TREATMENT- EMERGENT COMPLICATIONS OF STAGE III A NON-SMALL CELL CARCINOMA (NSCLC STAGE III A) IN PATIENTS TREATED WITH NEOADJUVANT CHEMORADIOTHERAPY (NHLT), (NCHT), AND NEOADJUVANT CHEMOTHERAPY AND ADJUVANT RADIATION THERAPY. Clinical and Preventive Medicine, (1), 26-29. https://doi.org/10.31612/2616-4868.1(23).2023.04

Abstract

Treatment of STAGE III A NSCLC is an extremely difficult problem for modern oncology, since the one-year survival rate from the moment of diagnosis according to the National Cancer Registry is up to 58%. At the same time, there is a situation of uncertainty in the clinical approach to the treatment of this pathology – neither NCCN nor other world scientific literature sources contain information regarding a specific treatment method. The advantage of none of the possible methods of treatment of stage III NSCLC (HCT, NHLT, HCT + adjuvant PT) is not proven in relation to others. The conducted study is devoted to comparing these methods in relation to each other and overall and relapse-free survival. According to the results of previous studies, the highest results of both general and relapse-free survival were shown by patients from the NHLT group. But an important aspect of treatment is the ratio of benefit and risk, that is, the number and severity of complications. The study and analysis of complications of treatment with the methods of NXT, NHLT and NXT + adjuvant PT was the task of the work. Goal. To investigate and determine the number of complications in groups with NCRT, NCT and NCT + adjuvant LT. Materials and methods. The study included 3 groups of patients – patients who received NHLT, NHT and NHT + adjuvant PT, a total of 304 people. All patients had the same chemotherapy regimen- Cisplatin / Docetaxel or Carboplatin / Paclitaxel, patients receiving radiation therapy received it in a total dosage of 30 Gy in both neoadjuvant and adjuvant regimens. The irradiation was carried out on the chest and mediastinum area. Patients underwent radical surgery in the form of lobectomy, bilobectomy or pneumonectomy. In early works on this topic, an analysis of survival on the Kaplan and Mayer scale was carried out. The article describes the conduct and study of treatment complications that were recorded during the stay of patients in the hospital both during chemotherapy, radiation therapy and in the postoperative period.

https://doi.org/10.31612/2616-4868.1(23).2023.04
ARTICLE PDF (Українська)

References

Національний реєстр раку. Available from: https://www.socialstyrelsen.se/en/statistics.

Maliarchuk Кaterina, Ganul Andrey V., Borisyuk Bogdan O., Bororov Leonid V., Shevchenko Anatoly I., Sovenko Vladimir M.. (2022). Prospects of neoadjuvant chemoradiotherapy in patients with stage iii a non-small cell lung cancer as a method of improving survival. Wiadomości Lekarskie, LXXV, 4, 2, 949 – 954.

Maliarchuk Кaterina, Ganul Andrey V., Borisyuk Bogdan O., Bororov Leonid V., Shevchenko Anatoly I., Sovenko Vladimir M.. (2022). Correlation of relapse-free survival with neoadjuvant treatment in patients with stage iiia non-small cell lung cancer. Wiadomości Lekarskie. LXXV, 9, 1, 2098-2102.

Zakharichev V., Bororov L., Shevchenko A., Malyarchuk K. (2019). Korelyatsiya stupenya morfolohichnoyi vidpovidi pukhlyny z vyzhyvanistyu pislya kompleksnoho likuvannya rezektabelʹnoho nedribnoklitynnoho raku leheni (NDRL) IIIA stadiyi [Correlation of the degree of tumor morphological response with survival after complex treatment of stage IIIA resectable non-small cell lung cancer (NSCLC) ]. Proceedings of the National Medical Academy named after P.L. Shupyka, 2, 2(20), 7.

Posibnyk NCCN z klinichnoyi praktyky v onkolohiyi (NCCN Guidelines®) nedribnoklitynnyy rak leheniv: versiya 3.2020 [NCCN Clinical Practice Guideline in Oncology (NCCN Guidelines®) Non-Small Cell Lung Cancer: Version 3.2020].

Lohan, D. M., Lokhrin, K. A., Darlinh, H. ta in. (1997). Ad'yuvantna promeneva terapiya ta khimioterapiya pry nedribnoklitynnomu raku leheniv II abo IIIA stadiyi pislya povnoyi rezektsiyi [Adjuvant radiotherapy and chemotherapy in stage II or IIIA non-small cell lung cancer after complete resection]. Provincial Group on Lung Cancer, 1(5), 366-378.

Hoss, H., Paszat, L., Nʹyuman, T. E. ta in. (1998). Zastosuvannya peredoperatsiynoyi khimioterapiyi z pislyaoperatsiynoyu promenevoyu terapiyeyu abo bez neyi pry tekhnichno rezektabelʹnomu nedribnoklitynnomu raku leheniv IIIA stadiyi. Kerivnytstvo po borotʹbi z poperednim rakom [Use of preoperative chemotherapy with or without postoperative radiation therapy in technically resectable stage IIIA non-small cell lung cancer. A guide to dealing with pre-cancer]. Provincial Lung Cancer Panel, 2(1), 32-9.

Kardenal, F., Palʹmero, R. (2017). Likuvannya rezektabelʹnoho nedribnoklitynnoho raku leheniv stadiyi IIIA [Treatment of stage IIIA resectable non-small cell lung cancer]. Thoracic Oncol., 12(2), 314-322. doi: 10.1016/j. jtho.2016.09.122.

Yuankay, S.I., Yan, S., Tszinmin, YU. ta in. (2016). Konsensus kytaysʹkykh ekspertiv shchodo diahnostyky ta likuvannya peredovoyi stadiyi pervynnoho raku leheniv (versiya 2016 roku) [Consensus of Chinese experts on the diagnosis and treatment of advanced stage primary lung cancer (2016 version)]. Asia Pacific Guidelines Journal. doi:10.1111/ajco.12608.

Hao, S.Dzh., Korso, K. D., Van, E. KH. ta in. (2016). Terminy operatsiyi pislya neoad'yuvantnoyi khimiopromenevoyi terapiyi pry mistsevo poshyrenomu nedribnoklitynnomu raku leheni [Terms of surgery after neoadjuvant chemoradiotherapy in locally advanced non-small cell lung cancer], 12(2), 314-322 doi: 10.1016/j.jtho.2016.09.122.

Koshi, M., Fedeva, S. A., Malik, R. ta in. (2013). Pokrashchena vyzhyvanistʹ, pov'yazana z neoad'yuvantnoyu khimiopromenevoyu terapiyeyu u patsiyentiv z nedribnoklitynnym rakom leheniv klinichnoyi stadiyi IIIA(N2) [Improved survival associated with neoadjuvant chemoradiotherapy in patients with clinical stage IIIA(N2) non-small cell lung cancer]. Thoracic oncologist, 8(7), 915-22. doi: 10.1097/JTO.0b013e31828f68b4.

Shakh, A.A., Berri, M. F., Tszao, S. ta in. (2012). Induktsiyna khimiopromeneva terapiya ne perevershuye tilʹky induktsiynu khimioterapiyu pry raku leheniv IIIA stadiyi [Induction chemotherapy is not superior to induction chemotherapy alone in stage IIIA lung cancer]. Thoracic Surgery, 93(6), 1807-12.doi: 10.1016/j. athoracsur.2012.03.018.

Tsvitter, M., Kovach, V., Smrdelʹ, U., Stroyan, P. Hemtsytabin, tsysplatyn ta hiperfraktsionovana pryskorena promeneva terapiya lokalʹno rozpovsyudzhenoho nedribnoklitynnoho raku leheniv. Klinichne vyprobuvannya [Gemcitabine, cisplatin and hyperfractionated accelerated radiotherapy for locally advanced non-small cell lung cancer. Clinical trial]. Torakalʹnyy onkol.

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.